PHAT Phathom Pharmaceuticals Inc
$11.76 $0.00 (0.00%)
15 Minute Delayed Price Enable Real-Time Price
Overall
PHAT Stock Analysis Overview
What this means: Phathom Pharmaceuticals Inc (PHAT) gets a very positive evaluation from InvestorsObserver's ranking system. An Overall Rank of 78 means that our comprehensive methodology rates Phathom Pharmaceuticals Inc above 78% of stocks.
Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.
Fundamental PREMIUM
PHAT Fundamental Analysis
Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.
Upgrade to Premium to unlock Fundamental Ranking
Short-Term Technical PREMIUM
PHAT Short-Term Technical Analysis
Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.
Upgrade to Premium to unlock Short-Term Technical Ranking
Long-Term Technical PREMIUM
PHAT Long-Term Technical Analysis
Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.
Upgrade to Premium to unlock Long-Term Technical Ranking
Analyst Ranking PREMIUM
PHAT Analyst Ranking
Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.
Upgrade to Premium to unlock Analyst Ranking Analysis
Valuation PREMIUM
PHAT Valuation Ranking Analysis
Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.
Upgrade to Premium to unlock Valuation Ranking
Stock Sentiment PREMIUM
PHAT Stock Sentiment Analysis
Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.
Upgrade to Premium to unlock Stock Sentiment Ranking
PHAT Stock Analysis Overview
What this means: Phathom Pharmaceuticals Inc (PHAT) gets a very positive evaluation from InvestorsObserver's ranking system. An Overall Rank of 78 means that our comprehensive methodology rates Phathom Pharmaceuticals Inc above 78% of stocks.
Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.
Create a FREE account to see full PHAT report
PHAT Fundamental Analysis
Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.
Upgrade to Premium to unlock Fundamental Ranking
PHAT Short-Term Technical Analysis
Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.
Upgrade to Premium to unlock Short-Term Technical Ranking
PHAT Long-Term Technical Analysis
Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.
Upgrade to Premium to unlock Long-Term Technical Ranking
PHAT Analyst Ranking
Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.
Upgrade to Premium to unlock Analyst Ranking Analysis
PHAT Valuation Ranking Analysis
Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.
Upgrade to Premium to unlock Valuation Ranking
PHAT Stock Sentiment Analysis
Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.